Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), filed a statement of changes in beneficial ownership on August 13, 2026, reporting a sale of common stock on August 11, 2026, in connection with the vesting of restricted stock units.

Key Highlights

  • Reporting person: Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc.
  • Transaction date: August 11, 2026, with the filing submitted on August 13, 2026.
  • Shares sold: 36,658 shares of common stock disposed of (transaction code S) at a price of $3.499 per share.
  • Purpose of sale: According to the filing, the shares were sold to pay tax withholding obligations in connection with the vesting of RSUs.
  • Remaining holdings: Following the transaction, Stevens beneficially owned 505,784 shares directly, including RSUs that convert to common stock on a one-for-one basis.

RSU Vesting and Share Sale Details for Rocket Pharmaceuticals COO

According to the filing, Stevens disposed of 36,658 shares of Rocket Pharmaceuticals common stock on August 11, 2026, at a price of $3.499 per share. The transaction was classified with code "S," indicating an open-market sale. The filing states that this sale was made specifically to cover tax withholding obligations arising from the vesting of restricted stock units, rather than as a discretionary open-market disposition.

Rocket Pharmaceuticals is a gene therapy company whose securities trade on NASDAQ under the symbol RCKT. The filing notes that Stevens's post-transaction holdings of 505,784 shares include restricted stock units that convert to common stock on a one-for-one basis, meaning the reported beneficial ownership figure encompasses both vested shares and outstanding RSU awards. The transaction was reported directly, with no indirect ownership structures disclosed. The filing was signed by Martin Wilson, acting as attorney-in-fact for Christopher James Stevens, on August 13, 2026.

No derivative securities transactions were reported in Table II of the filing. The ownership is listed as direct, and the filing was made by one reporting person only, with no indication that it constitutes an amendment to a prior filing.

What Was Disclosed

Rocket Pharmaceuticals COO Christopher James Stevens reported the sale of 36,658 common shares at $3.499 each on August 11, 2026, to satisfy tax withholding obligations tied to RSU vesting, leaving him with 505,784 shares beneficially owned directly.